LSD Gives Up a Secret
David Nichols, Ph.D. Saturday, April 22, 2017 • 9:00 AM - 9:30 AM • East Hall
Continuing Education (CE) • Continuing Medical Education (CME) • 0.5 Credits
This talk will give a very brief background on the chemistry and pharmacology of psychedelics. Most of the discussion will focus on LSD, and experiments that have been carried out to elucidate the orientation of LSD when it binds in its serotonin receptor targets. Included in the discussion will be comments on the recent publication of the x-ray crystal structure of LSD in the serotonin 5-HT2B receptor, and how those findings also relate to the likely binding orientation of LSD within its principal target, the serotonin 5-HT2A receptor.
David Nichols, Ph.D., was born on December 23, 1944 in Covington, Kentucky. He received a B.S. in Chemistry from the University of Cincinnati in 1969 and a Ph.D. in Medicinal Chemistry from the University of Iowa in 1973. His doctoral work at Iowa was supported by an NDEA-IV fellowship. He then accepted a postdoctoral appointment in the Department of Pharmacology at the University of Iowa College of Medicine, after which he began his career at Purdue. Nichols taught and researched at Purdue University from 1974 until his retirement in 2012. He received the Heine Best Teacher award from the School of Pharmacy in 1981, in 2004 was named the Irwin H. Page Lecturer by the International Society for Serotonin Research, and in 2006 he was named the first Provost’s Outstanding Graduate Mentor at Purdue. He held joint professorial appointments in the Departments of Medicinal Chemistry and Pharmacognosy, and of Pharmacology and Toxicology. From 1994 until 1996 he was the Interim Head of both Departments, and oversaw their merger into the current Department of Medicinal Chemistry and Molecular Pharmacology. He also held a joint appointment in the Indiana University School of Medicine, and taught in the medical curriculum at Purdue. In 2012 he was honored as an Outstanding Alumnus by the University of Iowa College of Pharmacy. Prior to his retirement, he was the Robert C. and Charlotte P. Anderson Distinguished Chair in Pharmacology and also a Distinguished Professor of Medicinal Chemistry and Molecular Pharmacology at the Purdue College of Pharmacy. He is currently an Adjunct Professor in the Eshelman School of Pharmacy at the University of North Carolina Chapel Hill, NC, where he continues research. During his years of research, Nichols appeared as an author of more than 300 scientific publications. Believing that psychedelic drugs could have positive therapeutic results, Nichols initiated the founding of the Heffter Research Institute in 1993 to support high-quality basic and clinical psychedelic research. Nichols also is known for coining the term ‘entactogen’ to differentiate the effects of MDMA and related chemicals from the phenethylamine hallucinogens. In addition to developing novel psychoactive substances in his lab at Purdue, the Nichols’ lab also synthesized high-purity MDMA, DMT, psilocybin, and other substances for research programs at other institutions. It became apparent to him that even if researchers could obtain the necessary approvals for their studies, there was no source for the pure drugs they required for human studies. Therefore, he made the DMT for Rick Strassman’s groundbreaking DMT study, published in 1994. The MDMA from his laboratory was used for most of the preclinical and all of the clinical studies employing MDMA from about 1986 until 2016, including Phase 2 clinical studies for the use of MDMA for treating post-traumatic stress disorder (PTSD.) Psilocybin made in his laboratory was used for Roland Griffith’s study of the effects of psilocybin in normal subjects, published in 2006, as well as for the Phase 2 clinical study of psilocybin-assisted treatment of distress in patients with a life-threatening diagnosis, published in 2016.
Nichols also had a parallel, but less well recognized, research track in discovering novel full efficacy agonists for the dopamine D1 receptor, and developed a number of such molecules, the first of which was named dihydrexidine. He was awarded eight patents in the field of dopamine D1 agonists. Studies published in 1986 reported that dihydrexidine was efficacious in reversing parkinsonian symptoms in a monkey model of Parkinson’s disease. This proof-of-principle study indicated that dopamine D1 agonists might be useful therapy in late stage Parkinson patients who had become resistant to the therapeutic effects of the gold standard treatment, levo-dopa. He was a cofounder in 2000 of a small biotech company in Chapel Hill, NC, known as DarPharma, Inc., which attempted to commercialize dopamine D1 agonists for use in Parkinson’s disease, as well as potential drugs to improve working memory in schizophrenia. The company was unable to commercialize his drugs and was bought in 2006.
Continuing Medical Education (CME) is available for physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Institute for Medical Quality/California Medical Association (IMQ/CMA) through the joint providership of CME Consultants and the Multidisciplinary Association for Psychedelic Studies (MAPS). CME Consultants is accredited by the IMQ/CMA to provide continuing medical education for physicians.
This activity is geared towards Psychiatrists and Primary Care Physicians.
Psychedelic Neuroscience David Nichols, Ph.D. – Adjunct Professor of Chemical Biology and Medicinal Chemistry, University of North Carolina at Chapel Hill; Founding President of the Heffter Research Institute DESIRED OUTCOMES: 1) Inform patients about new research into the pharmacological risks and effects of psychedelic compounds 2) Refer patients to clinical trials 3) Develop strategies for conducting their own pharmacological and neuroscientific research on psychedelics 4) Evaluate research on psychedelic-assisted treatments as new literature becomes available
*This activity will encompass the following desirable physician attributes: Patient Care & Procedural Skills, Medical Knowledge, Professionalism, Interpersonal & Communication Skills, Practice-Based Learning & Improvement, and Systems-Based Practice.